PFIZER INC

McKesson, Inc. 25 % 23 % 16 %

Cencora, Inc. 16 % 17 % 12 %

Cardinal Health, Inc. 13 % 14 % 10 %

During 2021 and 2022, we received significant purchase orders from Pfizer Inc. (“Pfizer”) for CDX-616, our proprietary enzyme product used in the manufacture of nirmatrelvir, a key component of Pfizer’s PAXLOVID product for the treatment of COVID-19 infections in humans.

Pfizer, Inc. 21.7 % * 15.6 % *

Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39%, 18%, 17%, 12% and 10% of our revenue, respectively, for the year ended December 31, 2024.Revenue by geographic area is based on the headquarters or shipping locations of our partners.

Multiple customers have provided more than 10% of total revenue in the periods presented, or accounted for more than 10% of accounts receivable at each respective balance sheet date, as follows: Revenue Accounts Receivable Three Months Ended September 30, Nine Months Ended September 30, September 30, 2025 December 31, 2024 2025 2024 2025 2024 ModernaTX, Inc. 19% 33% 25% 28% 11% * Regeneron Pharmaceuticals 19% * * * 19% * Pfizer Inc. 11% * * * 12% 25% Natera, Inc. * 20% 10% 31% * 13% Merck & Co., Inc. * * * * 18% 31% VA MVP * 17% 15% 11% * * * Less than 10% of revenue or accounts receivable.Significant Accounting PoliciesAs of September 30, 2025, the Company’s significant accounting policies are consistent with those discussed in Note 2 - “Summary of Significant Accounting Policies” in its consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermediates.

The increase in revenues recorded from sales to Pfizer resulted primarily from increased purchases of Elelyso by Pfizer to address unexpected manufacturing issues on their end.

The Company determined that Pfizer is a customer and that the Pfizer License Agreement is within the scope of ASC 606 as licensing intellectual property and performing ongoing research and development services are ordinary activities that are ongoing and central to the Company’s operations.